ArticleJournal of translational medicine2026
CD73-LNPs promote antitumor T-cell immunity via amplifying TLR3-mediated immunostimulatory dendritic cell activation.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundmRNA vaccines have emerged as highly promising therapeutic agents in cancer immunotherapy. Nevertheless, the current limited immunogenicity of target antigens and the lack of a robust systemic immune response remain significant challenges for their effective application. This study aimed to evaluate the immunogenicity of the CD73 protein and elucidate the mechanisms by which a CD73 mRNA vaccine mediates antitumor immune effects in murine models.
methodsCD73 mRNA was synthesized by in vitro transcription and formulated into lipid nanoparticles (CD73-LNPs) using a microfluidic device. The immunogenicity of CD73 was assessed using ELISPOT assays. The ability of CD73-LNPs to activate antitumor immune responses was evaluated by flow cytometry. Therapeutic efficacy was tested in murine models of melanoma, cervical cancer, ovarian cancer, and prostate cancer. Mechanistic insights were obtained through single-cell transcriptomics sequencing and bulk RNA transcriptomic analysis.
resultsThe CD73 protein exhibited potent immunogenicity. In vitro, CD73-LNPs promoted the maturation and activation of primary dendritic cells. In vivo, CD73-LNPs induced humoral and cellular immune responses, increased the secretion of interferon-gamma and granzyme B, and effectively suppressed tumor growth across multiple tumor models. Mechanistically, CD73-LNPs activated dendritic cells through toll-like receptor 3 (TLR3) signaling, enhanced dendritic cell activation, and upregulated chemokine receptor expression on CD8
conclusionCD73 mRNA vaccine safely and effectively induces antitumor immunity through TLR3-dependent mechanisms, highlighting their considerable potential for clinical translation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.